title: Four years' experience with the treatment of all-trans retinoic acid in acute promyelocytic leukemia.
abstract: A retrospective analysis was done on 43 patients with acute promyelocytic leukemia (APL) at our hospital from June 1987 to August 1992. All-trans retinoic acid was used to induce these patients to differentiation. In the early period of induction there were risks of severe hemorrhage, which was the main cause of early death. Treatments combined with platelets and heparin or aminomethylbenzoic (PAMBA) were given to patients with abnormal coagulation. As a result only 4 out of 43 patients died of intracranial bleeding at 4-12 days when their white blood cell (WBC) counts peaked. The combination of retinoic acid (RA) and HA chemotherapy could reduce hyperleukocytosis during the RA induction course. None of 7 patients died at early stage with this treatment combination. Our studies showed that it could predict the onset of remission at early stage through observations on the successive changes of karyotypes and morphology of the bone marrow and peripheral blood cells. Our studies also showed that the growth of CFU-F could be inhibited by RA. We think that it may play a role in the RA-induced differentiation. In 4 years of follow-up the overall leukemia-free survival (LFS) was 80% with a relapse rate of 45%. Thirty-five patients out of 43 cases were still alive in remission, and one was alive in relapse. All 11 out of 43 patients relapsed within 3 years, but the relapses occurred later, after 3 years duration of remission (P < .01). Retinoic acid failed to induce 5 patients who relapsed with the continuation treatment of RA and chemotherapy alternatively. In order to overcome the resistance to RA, the continuation treatment of simple chemotherapy had been administered following CR. Two cases achieved remission in this way. The difference of resistant events to RA reached significance between these 2 groups of different continuation treatment.
authors.affiliation: Department of Hematology, Jin Ling Hospital, Nanjing, China.
authors.forename: X
authors.initials: X
authors.lastname: Wu
authors.forename: X
authors.initials: X
authors.lastname: Wang
authors.forename: X
authors.initials: X
authors.lastname: Qien
authors.forename: H
authors.initials: H
authors.lastname: Liu
authors.forename: J
authors.initials: J
authors.lastname: Ying
authors.forename: Z
authors.initials: Z
authors.lastname: Yang
authors.forename: H
authors.initials: H
authors.lastname: Yao
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002884:Chromosomes, Human, Pair 15; D002886:Chromosomes, Human, Pair 17; D003643:Death; D005260:Female; D005347:Fibroblasts / Q000166:cytology; D006470:Hemorrhage / Q000209:etiology; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013234:Stem Cells; D013997:Time Factors; D014178:Translocation, Genetic; D014212:Tretinoin / Q000097:blood / Q000627:therapeutic use*
chemical_list: D014212:Tretinoin